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Abstract
Many (dietary) bitter compounds, e.g. flavonoids, activate bitter receptor hTAS2R39 in cell-based assays. Several flavonoids,
amongst which some flavanones, are known not to activate this receptor. As certain flavanones are known to mask bitter
taste sensorially, flavanones might act as bitter receptor antagonists. Fourteen flavanones were investigated for their
potential to reduce activation of hTAS2R39 by epicatechin gallate (ECG), one of the main bitter compounds occurring in
green tea. Three flavanones showed inhibitory behavior towards the activation of hTAS2R39 by ECG: 49-fluoro-6-
methoxyflavanone, 6,39-dimethoxyflavanone, and 6-methoxyflavanone (in order of decreasing potency). The 6-
methoxyflavanones also inhibited activation of hTAS2R14 (another bitter receptor activated by ECG), though to a lesser
extent. Dose-response curves of ECG at various concentrations of the full antagonist 49-fluoro-6-methoxyflavanone and
wash-out experiments indicated reversible insurmountable antagonism. The same effect was observed for the structurally
different agonist denatonium benzoate.
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Introduction
Even though bitter taste can be appreciated in some food
products, such as beer, coffee, dark chocolate and red wine [1], in
most cases bitterness in food is unwanted and efforts are taken to
reduce bitter taste [2]. One approach for masking bitter taste is the
use of so-called bitter receptor blockers, which inhibit the taste
receptor activation caused by the bitter compound. On the human
tongue, bitterness is perceived by human bitter taste receptors
(hTAS2Rs, TAS2Rs or T2Rs). The in-vitro activation of these
hTAS2Rs by bitter compounds has been studied intensively
during the last decade. For 21 of the 25 the bitter receptors, an
agonist, or in some cases dozens of agonists, have been identified
[3,4]. On the contrary, bitter receptor antagonists are still quite
rare.
The small molecule (4-(2,2,3-trimethylcyclopentyl)butanoic acid
(or GIV 3727) has been reported as inhibitor of six bitter taste
receptors [5]. It was able to decrease the sensory perception of
bitter aftertaste of the sweeteners acesulfame K and saccharin, as
well as the activation of hTAS2R31 and hTAS2R43, the bitter
receptors activated by these two compounds. Another compound,
the decreased bitter receptor activation of which could be linked to
sensory perception, was p-(dipropylsulfamyl)benzoic acid (better
known as probenecid). It has been reported to inhibit activation of
hTAS2R16, hTAS2R38, and hTAS2R43, and to suppress the
bitter taste perception of salicin in sensory tests [6]. It has been
reported that a compound can act as an agonist towards one
subset of bitter receptors, whereas it can act as an antagonist
towards another subset of bitter receptors. This has been described
for the two sesquiterpene lactones 3b-hydroxydihydrocostunolide
(3HDC) and 3b-hydroxypelenolide (3HP) [7].
Recently, a pharmacophore model for maskers of the bitter taste
of caffeine has been developed [8]. This pharmacophore was
docked into a homology model of hTAS2R10 (one of the bitter
receptors activated by caffeine). Docking of the two substances
enterolactone and enterodiol predicted their bitterness modulating
activities, which could be confirmed by sensory tests. Docking was
also applied for the compound GIV 3727 in a model of
hTAS2R31, and the presence of a single binding pocket was
reasoned [5], in which both agonist and antagonist can bind.
Apart from in-vitro studies on bitter receptor blocking, several
molecules are reported to mask bitter taste in-vivo [2], amongst
which the flavanones homoeriodictyol, its Na-salt, and eriodictyol.
They reduced the bitter taste of different chemical classes of bitter
molecules up to 40% with unknown mechanism [9]. Their
sensorial bitter masking effect has not been proven to be caused by
inhibition of bitter taste receptor activation. Two other flavanones
(sakuranetin and 6-methoxysakuranetin) have been described as
antagonists for hTAS2R31 [10]. Hence, flavanones seem to be of
importance in reduction of bitter taste and bitter taste receptor
activation.
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The human bitter taste receptor hTAS2R39 seems to be a bitter
receptor for dietary compounds, as many agonists are dietary
compounds, such as thiamine (vitamin B1), quinine [3] used in
tonic water, catechins from green tea [11], wine tannin precursors
[12], small peptides from casein hydrolysates [13] and cheese [14],
isoflavones from soy bean [15], and many other flavonoids from
several plant sources [16]. Hence, it is of interest to identify a bitter
blocker for this receptor. It is likely that an antagonist might have
similar structural elements to an agonist in order to fit into the
same binding pocket. In our previous study on (iso)flavonoid
agonists of hTAS2R39, several of the compounds tested, amongst
which flavanones, did not activate the bitter receptor despite
structural similarity to active compounds [16]. The aim of the
present study was to investigate whether these and other
flavanones could act as antagonists towards hTAS2R39. It was
demonstrated that some flavanones showed antagonistic behavior,
while others did not.
Materials and Methods
Materials
Compounds tested were obtained from Extrasynthese (Genay,
France), Indofine Chemical Company (Hillsborough, NJ, USA),
Interbioscreen (Moscow, Russia), and Sigma-Aldrich (Steinheim,
Germany). The majority of compounds were $99% or $98%
pure; compound (4) was 95% pure and compound (6) was 92–
95% pure. Each compound was dissolved in DMSO (Sigma-
Aldrich) to a 100 mM stock concentration. Trypan blue solution
(0.4% w/v) and isoproterenol were purchased from Sigma-
Aldrich.
Tyrode’s buffer (140 mM NaCl, 5 mM KCl, 10 mM glucose,
1 mM MgCl2, 1 mM CaCl2, and 20 mM Hepes, pH 7.4) with
0.5 mM probenecid (Sigma-Aldrich) was used for dilution of
compound-DMSO stock solutions and for calcium imaging assays.
The presence of probenecid in the buffer did not lead to inhibition
of hTAS2R14 or hTAS2R39. Comparisons of assays with and
without the use of probenecid are shown in File S1. All
compounds were tested for autofluorescence and toxic effects on
the cells (File S2) used at a concentration of 1 mM as described
before [15].
Expression of hTAS2R39 and hTAS2R14 in HEK293 cells
For functional expression of the human bitter taste receptor
hTAS2R39, HEK293 T-Rex Flp-In cells (Invitrogen, San Diego,
CA, USA) were used, stably expressing the chimeric G-protein a-
subunit Ga16-gust44 (cloned into pcDNA4 (Invitrogen)) [17] and
the human bitter receptor genes for hTAS2R39 (cloned into
pcDNA5/FRT (Invitrogen)). The bitter receptor gene contained a
DNA sequence encoding the first 45 amino acids of rat
somatostatin receptor type 3 at its 59 end (the receptor expression
was achieved according to [18] with exception of the HSV-tag), in
order to improve membrane targeting of the receptor protein. The
same procedure was applied for stable expression of hTAS2R14.
Cells were maintained in Dulbecco’s Modified Eagle’s Medium
(DMEM) and 10% (v/v) tetracycline-free FBS (both Lonza,
Verviers, Belgium) supplemented with blasticidin (5 mg/mL),
geneticin (400 mg/mL) and hygromycin (100 mg/mL) (all from
Invitrogen). Cells were grown and maintained at 37 uC and 5%
(v/v) CO2.
Monitoring bitter receptor activation by intracellular
calcium release
Cells were seeded into poly-L-lysine-coated (Sigma-Aldrich) 96-
well plates (black wall, clear bottom, Greiner bio-one, Frick-
enhausen, Germany) at a density of 7*103 cells in 100 mL/well and
cultured for 24 h. Transcription of the receptors was induced by
adding 0.25 mg/mL doxycycline (Sigma-Aldrich). Cells were
induced for 24 h and then loaded with the calcium-sensitive
fluorescent dye Fluo-4-AM (2.5 mM, Invitrogen), which was
dissolved in Tyrode’s buffer containing 5% (v/v) tetracycline-free
FBS (Lonza). One hour after loading, cells were washed with
Tyrode’s buffer and taken up in Tyrode’s buffer. Stock solutions of
test compounds were prepared in DMSO and diluted to the
appropriate concentration in Tyrode’s buffer, not exceeding a
DMSO concentration of 1% (v/v).
Receptor activation or inhibition was measured via intracellular
Ca2+ release [19] in a FlexStation II 384 or FlexStation III
(Molecular Devices Corporation, Sunnyvale, CA, USA) by
measuring fluorescence (excitation 485 nm/emission 520 nm) for
either 90 s or 240 s at 37uC. Two methods of compound
administration were applied: simultaneous and stepwise addition
of potential antagonist and agonist. The first 17 s before
compound addition were used for baseline determination. For
the simultaneous method, agonist and potential antagonist were
pre-mixed, administered after 17 s, and fluorescence was mea-
sured for in total 90 s. For the stepwise method, after 17 s, the
potential antagonist was added, fluorescence was measured until
120 s, and after 120 s the agonist was added and measured for
another 120 s, in total 240 s. Non-induced cells, which did not
express the taste receptor, were measured in parallel to verify
specificity of receptor activation. Each experiment was performed
at least in duplicate in separate experiments (as indicated for each
figure).
Calcium assay data processing
Data processing was done as reported previously [15]. In brief,
SoftMax Pro 5.4 software (Molecular Devices Corporation) was
used to plot the fluorescence signals. The fluorescence value (DF/
F0), representing receptor activity, was calculated by subtracting
the baseline fluorescence (F0) prior to loading from the maximum
fluorescence (F) after compound addition, divided by the signal of
Figure 1. Chemical structures of hTAS2R39 agonist epicatechin
gallate (ECG) (A), investigated flavanones (residues specified in
Table 1) (B) and hTAS2R39 agonist denatonium benzoate (C).
The commonly applied ring-nomenclature for flavonoids (A-, B-, and C-
ring) is shown in the general structure formula for flavanones.
doi:10.1371/journal.pone.0094451.g001
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the baseline in order to normalize background fluorescence [20].
Dose-response curves were established as non-linear regression
curves using Graph Pad Prism (version 4 for Windows, Graph Pad
Software, San Diego, CA, USA). Half-maximal effective concen-
trations (EC50) and half-maximal inhibitory concentrations (IC50)
were calculated. Error bars reflect the standard error of the mean
(SEM). Statistical analysis was performed in Graph Pad Prism
(one-way ANOVA at 5% risk level, followed by Bonferroni’s post
hoc test).
Investigation of inhibitory behavior of flavanones
Measuring dose-response curves of ECG on hTAS2R39 under
the conditions used in this study revealed an EC80 concentration of
200 mM. Screening for hTAS2R39 inhibition by flavanones was
performed with simultaneous application of agonist (200 mM




v1. In case of
indicated inhibition, flavanones were applied at different concen-
trations, in order to test for dose-dependent inhibition, at the EC80
concentration of the agonist. Another agonist of hTAS2R39,
denatonium benzoate, was used in inhibition experiments at
1.7 mM (EC80). hTAS2R14 inhibition was tested with 640 mM
ECG or 70 mM genistein as agonists, representing their respective
EC80 concentrations. To investigate the specificity of flavanones
for inhibition of hTAS2R39 and hTAS2R14, another bitter taste
receptor, hTAS2R16 (not known to be activated by flavonoids),
was used in inhibition experiments (File S3) towards its agonist
salicin.
To determine whether inhibition was specific for the bitter taste
receptor, the effect of the antagonists was tested on the b2-
adrenergic receptor agonist isoproterenol (50 mM). To this end,
the antagonists were applied at ,IC50 concentrations (100 mM 49-
fluoro-6-methoxyflavanone, 500 mM 6,39-dimethoxyflavanone,
and 500 mM 6-methoxyflavanone). To distinguish between
reversible and irreversible inhibition, washout experiments were
performed. Cells were stimulated with 200 mM ECG in the
Figure 2. Screening of flavanones for reduction of ECG response on hTAS2R39. Screening was performed with simultaneous application of




presented as mean 6SD of n separate experiments conducted in duplicate. Compounds 1, 2, 4, 5, 7, 10: n = 2, compounds 8, 9, 12, 13, 14: n = 3,
compound 3: n = 4, compound 6, 11: n = 5. Significance of signal reduction is indicated by ** (p#0.01) and * (p#0.05).
doi:10.1371/journal.pone.0094451.g002
Table 1. Flavanones tested for reduction of activation of
hTAS2R39 by ECG.
R5 R6 R7 R8 R39 R49
6-Chloro-4-methylflavanone (1) H Cl H H H CH3
8-Chloro-4-methylflavanone (2) H H H Cl H CH3
6,39-Dimethoxyflavanone (3) H OCH3 H H OCH3 H
Eriodictyola (4) OH H OH H OH OH
Flavanoneb (5) H H H H H H
49-Fluoro-6-methoxyflavanone (6) H OCH3 H H H F
Homoeriodictyola (7) OH H OH H OCH3 OH
6-Hydroxyflavanone (8) H OH H H H H
7-Hydroxyflavanone (9) H H OH H H H
49-Hydroxyflavanoneb (10) H H H H H OH
6-Methoxyflavanoneb (11) H OCH3 H H H H
7-Methoxyflavanone (12) H H OCH3 H H H
49-Methoxyflavanone (13) H H H H H OCH3
Sakuranetinc (14) OH H OCH3 H H OH
Residues relate to Figure 1B.
aactivated hTAS2R39 in a previous study [16], but was selected for testing as
antagonist due to ability to reduce bitter taste perception in sensory tests [9].
bno activation of hTAS2R39 in a previous study [16].
creported as antagonist of hTAS2R31 [10].
doi:10.1371/journal.pone.0094451.t001
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absence and in the presence of each antagonist (,IC50 concen-
trations), washed with Tyrode’s buffer (80 mL/well), and again
stimulated with 200 mM ECG.
Results
Identification and characterization of hTAS2R39
inhibitors
Epicatechin gallate (ECG) (Figure 1A), one of the main bitter
compounds in green tea [11], was chosen as agonist of
hTAS2R39. In a previous study we identified nine flavanones as
agonists of hTAS2R39, whereas three other flavanones did not
activate this receptor [16]. As some flavanones have been reported
as bitter blockers [9,10], it was investigated whether the three
inactive flavanones, as well as other flavanones, might have
antagonistic properties towards hTAS2R39. Fourteen flavanones
(Table 1 and Figure 1B) were screened for their ability to
reduce the activation of hTAS2R39 by ECG. Inhibition was
indicated when the ratio between ECG response in the presence of
a flavanone and the ECG response in the absence of a flavanone
was ,1 (Figure 2). In this figure, it can be seen that three
compounds showed reduction of ECG responses on hTAS2R39:
6,39-dimethoxyflavanone (3), 49-fluoro-6-methoxyflavanone (6),
and 6-methoxyflavanone (11). The inhibitory effects of (3) and (6)
at screening concentrations were significant. The effect of (11) was
not significant, but as there was a trend of reduced ECG responses
visible, also (11) was selected for investigation of dose-response
behavior.
They were further investigated by two different ways of
compound addition: simultaneous and stepwise addition. Simul-
taneous addition of agonist and antagonist to the receptor reflects
the situation of ideal blocker application in food products.
Stepwise addition of agonist and antagonist is commonly applied
in pharmaceutical research when examining pharmacodynamics
of receptor-antagonist interaction [21]. Figure 3 illustrates the
different ways of compound administration for representative
examples. Figure 3A shows simultaneous addition of agonist and
antagonist, which implies that after baseline fluorescence mea-
surement, agonist and antagonist were added simultaneously
(indicated with the arrow ‘‘1st addition’’). Figure 3B shows
stepwise addition of agonist and antagonist, which implies that
after baseline fluorescence measurement, first the antagonist (or
buffer) was added (indicated with the arrow ‘‘1st addition’’), and
subsequently the agonist was added (indicated with the arrow ‘‘2nd
addition’’). In both examples, calcium signals elicited by ECG
decreased in the presence of the 6-methoxyflavanones.
The inhibitory properties of the compounds 6,39-dimethoxy-
flavanone (3), 49-fluoro-6-methoxyflavanone (6), and 6-methoxy-
flavanone (11) towards hTAS2R39 were investigated using both
ways of compound addition. The compound 49-fluoro-6-methox-
yflavanone (6) showed inhibitory activity towards ECG on
hTAS2R39 both after simultaneous (Figure 4A) and after
stepwise addition (Figure 4B). Application of (6) prior to addition
of ECG led to 100% receptor blocking (Figure 4B). For this full
receptor blocker, the half-maximal inhibitory concentration (IC50)
was 102 mM. An overview of inhibition thresholds and IC50 values
is given in Table 2. When (6) was added simultaneously with
ECG, it had a lower inhibition threshold than when added in the
stepwise way. Upon simultaneous addition, a maximal signal
reduction of 65% was reached at 63 mM, and further signal
reduction could not be observed due to non-specific signals of the
compound itself. The same holds for the simultaneous addition of
Figure 3. Fluorescent counts of ECG-induced calcium responses in cells expressing hTAS2R39 (induced) and non-expressing
hTAS2R39 (non-induced). A: Simultaneous addition of agonist (ECG 200 mM) and antagonist (49-fluoro-6-methoxyflavanone (6) 16 mM) (%) versus
the signal elicited by ECG (antagonist replaced by buffer, final concentration ECG 200 mM) (e). Non-induced cells: ECG 200 mM and 49-fluoro-6-
methoxyflavanone (6) 16 mM (#) and ECG 200 mM (D). B: Stepwise addition of first antagonist (arrow ‘‘1st addition’’), and then agonist (arrow ‘‘2nd
addition’’) (1st 6-methoxyflavanone (11) 500 mM, 2nd ECG 200 mM) (%)) versus agonist (1st buffer, 2nd ECG 200 mM) (e). Non-induced cells: 1st 6-
methoxyflavanone (11) 500 mM, 2nd ECG 200 mM (#) versus 1st buffer, 2nd ECG 200 mM (D).
doi:10.1371/journal.pone.0094451.g003
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Figure4. Inhibitionof responseof 200mMECG (---)onhTAS2R39 (induced ( ), non-induced (N #)) by49-fluoro-6-methoxyflavanone (6) after
simultaneous addition (n=5) (A) and stepwise addition (n=4) (B), by 6,39-dimethoxyflavanone (3) after simultaneous addition (n=4) (C)
D), and by 6-methoxyflavanone (11) after simultaneous addition (n=5) (E) and stepwise addition (n=3) (F).
6SEM of n separate experiments conducted in duplicate.
doi:10.1371/journal.pone.0094451.g004
Table 2. Thresholds and IC50 values of 6-methoxyflavanones for inhibition of hTAS2R39 responses towards 200 mM ECG and
1.7 mM denatonium benzoate.
hTAS2R39 agonists Flavanones Simultaneous Stepwise
ECG Denatonium Threshold IC50 Threshold IC50
(mM) (mM) (mM) (mM) (mM) (mM)
200 0 6-methoxyflavanone n.b. n.b. 250 4796199
200 0 6,3-dimethoxyflavanone 63 282697 125 407655
200 0 49-fluoro-6-methoxyflavanone 8 3267 63 10269
0 1.7 6-methoxyflavanone n.b. n.b. 500 n.d.
0 1.7 6,3-dimethoxyflavanone 8 8966 63 24068
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and stepwise addition (n=3) (
Data are presented as mean
6,3-dimethoxyflavanone (3) (Figure 4C), where a maximal signal
reduction of 55% was reached at 500 mM. Due to increasing non-
specific signals of (3), the full efficacy upon simultaneous addition
could not be established. As shown in Figure 4D, a maximal
reduction of ,85% at 1000 mM was reached by (3) after stepwise
addition. In contrast to (6) and (3), the compound 6-methoxy-
flavanone (11) showed negligible inhibitory activity against ECG
on hTAS2R39 when applied simultaneously (Figure 4E), whereas
it showed inhibitory activity when applied stepwise (ca. 50%
reduction of activation at 500 mM) (Figure 4F). When investi-
gating the inhibitory behavior of the compounds identified, it thus
became clear that the way of antagonist addition influenced the
efficacy of the antagonist.
Next, it was investigated whether the activation of hTAS2R39
by another agonist could also be reduced by the inhibitors
identified. Denatonium benzoate (Figure 1C) was selected as well
known agonist of hTAS2R39, which is different from ECG, in
terms of structure and activation concentrations. Dose-response
curves of denatonium benzoate were measured, and an EC50 of
711 mM, and an EC80 of 1.7 mM were established (data not
shown). Figure 5 shows the inhibitory behavior of 49-fluoro-6-
methoxyflavanone (6) towards 1.7 mM denatonium benzoate on
hTAS2R39. The same trends as for ECG combined with
antagonists were observed. The receptor activation of denatonium
benzoate was reduced upon simultaneous addition of (6) up to a
concentration of 63 mM (not further reduced due to increasing
non-specific signals), leading to maximal signal reduction of 58%.
Stepwise application of (6) led to 100% receptor blocking, as
already seen with ECG. The IC50 was calculated to be 55 mM.
The results of all antagonists applied with denatonium benzoate
are summarized in Table 2. Due to the fact that structurally
different agonists were inhibited in a similar manner, we conclude
that the reduced receptor response was not achieved by interaction
between agonist and inhibitor, but by actual receptor antagonism.
Specificity of hTAS2R39 inhibitors
It was investigated whether the antagonists identified specifically
inhibit hTAS2R39, or also hTAS2R14, as many flavonoids
behave similarly towards these two receptors [16]. As agonist for
hTAS2R14, ECG was used. Figure 6 shows that no blocking of
hTAS2R14 occurred upon simultaneous application of 49-fluoro-
6-methoxyflavanone (6) and ECG (here at 640 mM, EC80 on
hTAS2R14). The increase of signal at increasing concentrations of
(6) is of non-specific nature, which can also be seen in the increase
of response of non-induced cells, in which the bitter receptor is not
expressed. Upon stepwise application, an inhibitory effect was
observed. The three methoxyflavanones were also tested with
genistein, another agonist of hTAS2R14, at 70 mM (EC80). The
results were similar to the results obtained with ECG. An overview
of inhibition thresholds and IC50 values on hTAS2R14 is given in
Table 3. It is remarkable that none of the three methoxy-
flavanones blocked hTAS2R14, when applied simultaneously with
one of the agonists.
Figure 5. Inhibition of response of 1.7 mM denatonium benzoate (---) on hTAS2R39 (induced ( ), non-induced (N #)) by 49-fluoro-6-
methoxyflavanone (6) after simultaneous addition (n=4) (A) and stepwise addition (n=4) (B). Data are presented as mean 6SEM of n
separate experiments conducted in duplicate.
doi:10.1371/journal.pone.0094451.g005
Figure 6. Inhibition of response of 640 mM ECG (---) on hTAS2R14 (induced (N), non-induced (#)) by 49-fluoro-6-methoxyflavanone
(6) after simultaneous addition (n=2) (A) and stepwise addition (n=3) (B). Data are presented as mean ±SEM of n separate
experiments conducted in duplicate.
doi:10.1371/journal.pone.0094451.g006
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In order to further investigate the specificity of the antagonists
identified towards taste receptors, isoproterenol responses were
measured. Inhibition of isoproterenol response would indicate
non-specific inhibition of b2-adrenergic receptors, endogenous to
HEK293 cells. The results (Figure 7) show that the isoproterenol
responses were not reduced and therewith the inhibition is
concluded to be specific for taste receptors. Furthermore, the
specificity of the antagonists was further investigated by measuring
their activity on another bitter taste receptor, hTAS2R16. No
blocking of salicin responses on hTAS2R16 was observed, neither
during simultaneous, nor stepwise addition (File S3).
Pharmacological characterization of 49-fluoro-6-
methoxyflavanone
Due to full elimination of agonistic responses by 49-fluoro-6-
methoxyflavanone (6) on hTAS2R39, this molecule seemed to be
the most effective antagonist identified in this study. The
mechanism of antagonism was further clarified by measuring
dose-response curves of ECG (Figure 8A) and denatonium
benzoate (Figure 8B) in the presence of various concentrations of
(6). Two effects were observed upon increasing antagonist
concentrations: the dose-response curves shifted to the right, and
the signal amplitudes decreased. The dose-response curves for the
inhibition of ECG and denatonium benzoate showed the same
pattern. EC50 values at all antagonist concentrations were
calculated and are given in Table 4.
To distinguish between reversible and irreversible inhibition,
washout experiments were performed. In Figure 8C it can clearly
be seen that the inhibition was reversible.
Discussion
In this paper we describe, to our knowledge for the first time,
the identification of antagonists for hTAS2R39. For hTAS2R39,
49-fluoro-6-methoxyflavanone (6), 6,39-dimethoxyflavanone (3),
and 6-methoxyflavanone (11) were identified as antagonists (in
decreasing order of potency), amongst which (6) fully eliminated
the agonistic response. This was observed both for the bitter tea
flavonoid ECG and for the synthetic bitter compound denatonium
benzoate. The activation of hTAS2R14, another bitter receptor
recognizing ECG [16], was also inhibited by the three flavanones,
though to a lesser extent. A mechanistic explanation for different
effects observed after simultaneous and stepwise application,
remains to be established.
In view of the fact that the application of (11) and (3) did not
lead to full inhibition of the ECG signal on hTAS2R39, the
question arises whether these two compounds are antagonists or
partial agonists. They were tested for hTAS2R39 agonism as well,
but none of them activated the receptor (File S4). Hence, they
probably act as real antagonists.
Structural requirements for hTAS2R39 antagonists
Several flavanones similar to the antagonists identified did not
show inhibitory activity towards bitter receptor hTAS2R39. It
turned out that only flavanones with a methoxy group on the 6-
position of the A-ring, and various B-ring configurations were able
to act as antagonists of hTAS2R39, as flavanone (5) (substitution of
flavanone crucial for inhibition), 6-hydroxyflavanone (8) (methoxy-
substitution crucial for inhibition), 49-methoxyflavanone (13) (A-
ring methoxylation crucial for inhibition), and 7-methoxyflava-
none (12) (6-position crucial for inhibition) did not show inhibitory
activity. Additionally, the compound 6-methoxyflavone was
Table 3. Thresholds and IC50 values of 6-methoxyflavanones for inhibition of hTAS2R14 responses towards 640 mM ECG and
70 mM genistein.
hTAS2R14 agonists Flavanones Simultaneous Stepwise
ECG Genistein Threshold IC50 Threshold IC50
(mM) (mM) (mM) (mM) (mM) (mM)
640 0 6-methoxyflavanone n.b. n.b. 250 4476123
640 0 6,3-dimethoxyflavanone n.b. n.b. 125 ,250
640 0 49-fluoro-6-methoxyflavanone n.b. n.b. ,8 79625
0 70 6-methoxyflavanone n.b. n.b. 500 7416143
0 70 6,3-dimethoxyflavanone n.b. n.b. n.d. n.d.




Figure 7. Isoproterenol responses upon application with
buffer, 49-fluoro-6-methoxyflavanone (6), 6,39-dimethoxyflava-
none (3), and 6-methoxyflavanone (11). Data are presented as
mean 6SEM of a representative experiment conducted in quadrupli-
cate. n.s., not significant.
doi:10.1371/journal.pone.0094451.g007
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unable to inhibit hTAS2R39 activation (data not shown), which
indicated that absence of a double bond in the C-ring is essential
for inhibition.
Amongst the antagonists identified for hTAS2R39, the differ-
ence in substitution of the B-ring determined the blocking potency.
Compound (11), which is unsubstituted on the B-ring, showed
poor blocking behavior compared to (6) and (3). It might be
speculated that size, electronegativity and/or electron withdrawing
effect of the B-ring substituent influences the potency of
antagonists.
Pharmacological characterization of 49-fluoro-6-
methoxyflavanone
Due to full elimination of agonistic responses (at their EC80
concentrations) by 49-fluoro-6-methoxyflavanone (6) on
hTAS2R39, this molecule was investigated further with respect
to a possible antagonistic mechanism. Two effects were observed
when increasing 49-fluoro-6-methoxyflavanone concentrations: the
dose-response curves shifted to the right, and the signal amplitudes
decreased. These phenomena suggest that it can be classified as
insurmountable antagonist [22]. This curve pattern can be an
indication for three different mechanisms: (i) irreversible antago-
nism, (ii) reversible non-competitive orthosteric antagonism, in
which an equilibrium is not reached, and (iii) reversible
insurmountable allosteric antagonism [22]. Washout experiments
(Figure 8C) clearly showed that the ECG responses after
washing-out the antagonist were similar to the ECG responses
prior to application of the antagonist. It can thus be concluded that
the interaction was reversible. In order to distinguish between (ii)
and (iii), two aspects can be studied: (a) whether the antagonist is
probe dependent, meaning that its antagonistic characteristics
Figure 8. Dose-response curves for epicatechin gallate (ECG) (N) (n=2) (A) and denatonium benzoate (N) (n =2) (B) on hTAS2R39,
and their modification by increasing 49-fluoro-6-methoxyflavanone (6) concentrations (# 50 mM, D 100 mM,% 200 mM). Antagonist
and agonist were added in the stepwise way. Data are presented as mean 6SEM of n separate experiments conducted in duplicate. Wash-out
experiments (n = 2) (C). Cells were stimulated with 200 mM ECG in the absence (open bars) and in the presence (filled bars) of 100 mM 49-fluoro-6-
methoxyflavanone (6), or 500 mM 6,39-dimethoxyflavanone (3), or 500 mM 6-methoxyflavanone (11), washed with Tyrode’s buffer, and again
stimulated with 200 mM ECG (hatched bars; control: grey bar). Antagonist and agonist were added in the stepwise way. Data are presented as mean
6SEM of n separate experiments conducted in quadruplicate. Significance of signal reduction is indicated by *** (p#0.001), ** (p#0.01), and n.s. (not
significant, p.0.05).
doi:10.1371/journal.pone.0094451.g008
Table 4. EC50 values of ECG and denatonium benzoate in the presence of various concentrations of 49-fluoro-6-methoxyflavanone
(6) on hTAS2R39.
Concentration of 49-fluoro-6-methoxyflavanone
0 mM 50 mM 100 mM 200 mM
ECG 128682 mM 156663 mM 501648 mM 781693 mM
Denatonium benzoate 6596334 mM 1.0960.21 mM 3.3660.84 mM 6.9464.98 mM
doi:10.1371/journal.pone.0094451.t004
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(reflected in curve shapes) are different towards structurally
different agonists, and (b) whether the effect of the antagonist is
saturable, meaning that no antagonist concentration can lead to
full agonist signal elimination. Probe dependence (a) and
saturability (b) indicate mechanism (iii) [22]. When the inhibition
behavior of 49-fluoro-6-methoxyflavanone was studied with two
structurally different agonists, it was observed that the synthetic
hTAS2R39 agonist denatonium benzoate was also inhibited by 49-
fluoro-6-methoxyflavanone (Figure 8B), and exhibited a curve
pattern almost alike that by ECG (Figure 8A) upon different
blocker concentrations. These analogous results for the two
structurally different agonists might on the one hand indicate
orthosteric antagonism, but on the other hand they do not
completely exclude allosteric antagonism. If the antagonist would
have been unable to inhibit a structurally different agonist, it
would strongly suggest allosteric antagonism. However, determi-
nation of allosterism by observing probe dependence is a one-way
relationship [22], meaning that the absence of probe dependence
is no definite proof for orthosterism. The same holds for
saturability, which was not examined.
For hTAS2R46, hTAS2R31, hTAS2R43 [23], hTAS2R16
[24], and hTAS2R38 [25], docking simulations into homology
models, validated by site-directed mutagenesis, have predicted the
presence of a single binding pocket in the respective bitter
receptors. Furthermore, the mechanism of antagonism of
GIV3727 on hTAS2R31 was described as orthosteric, insur-
mountable antagonism [5], supported by docking the antagonist
into the same binding pocket as the agonist. In contrast, one study
suggests allosteric antagonism as mechanism for inhibition of
hTAS2R16 and hTAS2R38 by probenecid [6]. No information
has been reported yet on the binding pocket of hTAS2R39. As the
majority of studies suggests the presence of a single binding pocket
in different bitter receptors, and the relatively small extracellular
domain of bitter receptors offers little space for another binding
site (in contrast to sweet receptors, where a second binding site is
present in the large N-terminal extracellular domain [26]), an
orthosteric mechanism seems more likely for explaining our
observations. However, at the antagonist concentrations tested, no
full signal elimination was reached, and thus the possibility of an
allosteric mechanism cannot be ruled out.
Application of bitter receptor blockers
For application of blockers in food products, several require-
ments should be met. (i) The blocker should be functional at a low
dose. Therefore, an antagonist that has to be applied in equimolar
or higher quantity to the agonist, is not efficient. (ii) In order to
block the bitter taste of dietary compounds, for practical reasons, it
is necessary that a bitter receptor blocker is also functional when
applied simultaneously with the bitter compound. Therefore,
compounds like (3) and (6) seem to be more suitable than (11). (iii)
In order to achieve a sensorial effect, blocking of all bitter
receptors activated by one compound is desirable. A blocker, that
can only inhibit hTAS2R39, but not hTAS2R14, might be too
specific to effectively reduce bitterness of ECG. On the other
hand, it is not known yet whether these two receptors have an
equally important role in the mouth. (iv) The blocker should
preferably be of natural origin, and should be available in
sufficient quantity. We could not find any natural source of the
three inhibitors described in this study, and assume that they are
only available synthetically. (v) Only compounds that are known as
safe for consumption are of interest for food applications. Due to
unknown safety of 49-fluoro-6-methoxyflavanone, we abstained
from sensory tests, which might confirm the function as bitter taste
blocker in-vivo. As not all criteria are met by the blockers
discovered in the present study, they might not be applicable to
food products. Nevertheless, a 6-methoxy substituent on the A-
ring of a flavanone has been identified as important for inhibition
of hTAS2R39, which might form the basis for other, more
suitable, blockers.
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